• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MEM 16.7% 0.5¢

MEMPHASYS LIMITED. - Announcements

Memphasys Limited is an Australia-based reproductive biotechnology company. The Company... Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The Company's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk

MEMAppendix 3Y and Form 60430/12/13
MEMPrIME receives Xeraya Board conditional approval for FundingPRICE SENSITIVE24/12/13
MEMCompany Secretary Change19/12/13
MEMNuSep Board Appointment02/12/13
MEMNuSep Board Changes29/11/13
MEMNuSep Results of AGM29/11/13
MEMNuSep 2013 AGM Presentation29/11/13
MEMAppendix 3Y and Form 60427/11/13
MEMAnnual Report31/10/13
MEMNotice of Annual General Meeting as mailed to Shareholders30/10/13
MEMNotice of Annual General Meeting/Proxy Form30/10/13
MEMBoard Changes29/10/13
MEMPrIME signs Non Binding Funding Term SheetPRICE SENSITIVE29/10/13
MEMNuSep Receives $1.6m R&D Tax RefundPRICE SENSITIVE08/10/13
MEMAnnual Financial Report 30 June 201301/10/13
MEMAppendix 3B16/09/13
MEMNuSep Presents at Bioplasma Conference06/09/13
MEMChange in substantial holding x 230/08/13
MEMNuSep announces 30 June 2013 Full Year ResultsPRICE SENSITIVE30/08/13
MEMIncrease in Director Holdings29/08/13
MEMNuSep Restatement of Prior Period Accounts29/08/13
MEMNuSep Raises $1.2m under SPP26/08/13
MEMNuSep lodges $1.6m R&D Tax RefundPRICE SENSITIVE23/08/13
MEMRelodgement of Initial Substantial Shareholder21/08/13
MEMBecoming a substantial holder21/08/13
MEMNuSep 2013 SPP Closes20/08/13
MEMUpdate on Settlement for the Acquisition of Singapore cGMP F19/08/13
MEMNuSep Investor Presentation - SPP08/08/13
MEMNuSep Shareholder Newsletter07/08/13
MEMNuSep SPP Update & Investor Meetings02/08/13
MEMUpdate on PrIME LOI FundingPRICE SENSITIVE29/07/13
MEMNuSep Share Purchase Plan 201323/07/13
MEMSection 708A SPP Cleansing Statement23/07/13
MEMFunding Update & SPP AnnouncementPRICE SENSITIVE22/07/13
MEMInitial Substantial Shareholder17/07/13
MEMResearch Report on NuSep10/07/13
MEMNuSep Investor Presentation10/07/13
MEMNuSep Announces Long Term Debt ManagementPRICE SENSITIVE09/07/13
MEMChange of Address & Registered Office05/07/13
MEMNuSep - New Headquarters24/06/13
MEMPrIME Receives Plasma Importation LicensePRICE SENSITIVE11/06/13
MEMNuSep Signs LOI to Fund PrIMEPRICE SENSITIVE03/06/13
MEMCompany Secretary Update03/06/13
MEMFirst PrIME Franchise ProposalPRICE SENSITIVE30/05/13
MEMDengue Diagnostic & Therapeutic - New Application of PrIMEPRICE SENSITIVE23/05/13
MEMNuSep Appoints KPMG as Company Auditor21/05/13
MEMNuSep UpdatePRICE SENSITIVE20/05/13
MEMPrIME UpdatePRICE SENSITIVE15/05/13
MEMNSP Cleansing Notice08/05/13
MEMResignation of Auditor01/05/13
MEMNuSep Singapore PrIME Fundraising and Appendix 3BPRICE SENSITIVE01/05/13
MEMDivestiture of non-core ProteoIQ software15/03/13
MEMReinstatement to Official QuotationPRICE SENSITIVE01/03/13
MEMNuSep Half Year Report & AccountsPRICE SENSITIVE01/03/13
AEJ +Suspension from Official QuotationPRICE SENSITIVE01/03/13
MEMAppointment of New Company Secretary15/02/13
MEMUpdated NuSep Charters25/01/13
MEMCeasing to be a substantial holder24/01/13
MEMBecoming a substantial holder24/01/13
MEMNuSep divests non Core ProteoIQ softwarePRICE SENSITIVE24/01/13
MEMPrIME Completes lease for Singapore cGMP Facility10/01/13
MEMSubstantial Shareholder Notice09/01/13
MEMChange in substantial holding08/01/13
MEMPrIME completes first three trial production runs of AlbuminPRICE SENSITIVE08/01/13
MEMNuSep receives Final Tranche payment and Appendix 3B02/01/13
MEMNuSep Receives $1.54m R&D Tax Refund17/12/12
MEMResponse to ASX Letter re Disclaimer of Audit Opinion13/12/12
MEMChange of Director's Interest Notice11/12/12
MEMAmendment of 2012 AGM Poll numbers11/12/12
MEMChange of Director's Interest Notice - Manusu, Nair, Goodall06/12/12
MEMAppendix 3B06/12/12
MEMFinal Director's Interest Notices04/12/12
MEMUpdate on PrIME Spin Out ResolutionPRICE SENSITIVE04/12/12
MEMInitial Director's Interest Notice - P Patel and C Eu04/12/12
MEMResults of Meeting30/11/12
MEMBoard UpdatePRICE SENSITIVE30/11/12
MEMShareholder Update30/11/12
MEMBoard Changes28/11/12
MEMAppendix 3B22/11/12
MEMProf John Aitken Awarded as NSW Scientist of the Year 201215/11/12
MEMNuSep achieves TGA accreditation for DiagnosticsPRICE SENSITIVE12/11/12
MEMBecoming a substantial holder02/11/12
MEMCleansing Notice02/11/12
MEMNuSep Annual Report 201231/10/12
MEMNuSep NOM 2012 AGM and EGM30/10/12
MEMAppendix 3B30/10/12
MEMNuSep Makes a 15% PlacementPRICE SENSITIVE30/10/12
MEMNuSep Updated Board Charters30/10/12
MEMCorrection to Spin Out of PrIME Biologics And Update of Time30/10/12
MEMNuSep clears shares held in suspense account29/10/12
MEMNuSep 2012 AGM15/10/12
MEMSpin Out of PrIME BiologicsPRICE SENSITIVE15/10/12
MEMCritical Milestone with Installation of PrIME unit in SingapPRICE SENSITIVE03/10/12
MEMSubstantial Shareholder Notice02/10/12
MEMAnnual Financial Report 30 June 201228/09/12
MEMNuSep Working Capital Advance and update on DCS DebtPRICE SENSITIVE27/09/12
MEMResearch Report on NuSep06/09/12
MEMNuSep announces 30 June 2012 Full Year ResultsPRICE SENSITIVE30/08/12
MEMUpdate on PrIME Developments and impact on 30.06.12 resultsPRICE SENSITIVE28/08/12
MEMNotice to holders of 35 cent options (NSPO)21/08/12
MEMAppendix 3Y and Form 604
30/12/13
MEMPrIME receives Xeraya Board conditional approval for Funding
24/12/13PRICE SENSITIVE
MEMCompany Secretary Change
19/12/13
MEMNuSep Board Appointment
02/12/13
MEMNuSep Board Changes
29/11/13
MEMNuSep Results of AGM
29/11/13
MEMNuSep 2013 AGM Presentation
29/11/13
MEMAppendix 3Y and Form 604
27/11/13
MEMAnnual Report
31/10/13
MEMNotice of Annual General Meeting as mailed to Shareholders
30/10/13
MEMNotice of Annual General Meeting/Proxy Form
30/10/13
MEMBoard Changes
29/10/13
MEMPrIME signs Non Binding Funding Term Sheet
29/10/13PRICE SENSITIVE
MEMNuSep Receives $1.6m R&D Tax Refund
08/10/13PRICE SENSITIVE
MEMAnnual Financial Report 30 June 2013
01/10/13
MEMAppendix 3B
16/09/13
MEMNuSep Presents at Bioplasma Conference
06/09/13
MEMChange in substantial holding x 2
30/08/13
MEMNuSep announces 30 June 2013 Full Year Results
30/08/13PRICE SENSITIVE
MEMIncrease in Director Holdings
29/08/13
MEMNuSep Restatement of Prior Period Accounts
29/08/13
MEMNuSep Raises $1.2m under SPP
26/08/13
MEMNuSep lodges $1.6m R&D Tax Refund
23/08/13PRICE SENSITIVE
MEMRelodgement of Initial Substantial Shareholder
21/08/13
MEMBecoming a substantial holder
21/08/13
MEMNuSep 2013 SPP Closes
20/08/13
MEMUpdate on Settlement for the Acquisition of Singapore cGMP F
19/08/13
MEMNuSep Investor Presentation - SPP
08/08/13
MEMNuSep Shareholder Newsletter
07/08/13
MEMNuSep SPP Update & Investor Meetings
02/08/13
MEMUpdate on PrIME LOI Funding
29/07/13PRICE SENSITIVE
MEMNuSep Share Purchase Plan 2013
23/07/13
MEMSection 708A SPP Cleansing Statement
23/07/13
MEMFunding Update & SPP Announcement
22/07/13PRICE SENSITIVE
MEMInitial Substantial Shareholder
17/07/13
MEMResearch Report on NuSep
10/07/13
MEMNuSep Investor Presentation
10/07/13
MEMNuSep Announces Long Term Debt Management
09/07/13PRICE SENSITIVE
MEMChange of Address & Registered Office
05/07/13
MEMNuSep - New Headquarters
24/06/13
MEMPrIME Receives Plasma Importation License
11/06/13PRICE SENSITIVE
MEMNuSep Signs LOI to Fund PrIME
03/06/13PRICE SENSITIVE
MEMCompany Secretary Update
03/06/13
MEMFirst PrIME Franchise Proposal
30/05/13PRICE SENSITIVE
MEMDengue Diagnostic & Therapeutic - New Application of PrIME
23/05/13PRICE SENSITIVE
MEMNuSep Appoints KPMG as Company Auditor
21/05/13
MEMNuSep Update
20/05/13PRICE SENSITIVE
MEMPrIME Update
15/05/13PRICE SENSITIVE
MEMNSP Cleansing Notice
08/05/13
MEMResignation of Auditor
01/05/13
MEMNuSep Singapore PrIME Fundraising and Appendix 3B
01/05/13PRICE SENSITIVE
MEMDivestiture of non-core ProteoIQ software
15/03/13
MEMReinstatement to Official Quotation
01/03/13PRICE SENSITIVE
MEMNuSep Half Year Report & Accounts
01/03/13PRICE SENSITIVE
AEJ +Suspension from Official Quotation
01/03/13PRICE SENSITIVE
MEMAppointment of New Company Secretary
15/02/13
MEMUpdated NuSep Charters
25/01/13
MEMCeasing to be a substantial holder
24/01/13
MEMBecoming a substantial holder
24/01/13
MEMNuSep divests non Core ProteoIQ software
24/01/13PRICE SENSITIVE
MEMPrIME Completes lease for Singapore cGMP Facility
10/01/13
MEMSubstantial Shareholder Notice
09/01/13
MEMChange in substantial holding
08/01/13
MEMPrIME completes first three trial production runs of Albumin
08/01/13PRICE SENSITIVE
MEMNuSep receives Final Tranche payment and Appendix 3B
02/01/13
MEMNuSep Receives $1.54m R&D Tax Refund
17/12/12
MEMResponse to ASX Letter re Disclaimer of Audit Opinion
13/12/12
MEMChange of Director's Interest Notice
11/12/12
MEMAmendment of 2012 AGM Poll numbers
11/12/12
MEMChange of Director's Interest Notice - Manusu, Nair, Goodall
06/12/12
MEMAppendix 3B
06/12/12
MEMFinal Director's Interest Notices
04/12/12
MEMUpdate on PrIME Spin Out Resolution
04/12/12PRICE SENSITIVE
MEMInitial Director's Interest Notice - P Patel and C Eu
04/12/12
MEMResults of Meeting
30/11/12
MEMBoard Update
30/11/12PRICE SENSITIVE
MEMShareholder Update
30/11/12
MEMBoard Changes
28/11/12
MEMAppendix 3B
22/11/12
MEMProf John Aitken Awarded as NSW Scientist of the Year 2012
15/11/12
MEMNuSep achieves TGA accreditation for Diagnostics
12/11/12PRICE SENSITIVE
MEMBecoming a substantial holder
02/11/12
MEMCleansing Notice
02/11/12
MEMNuSep Annual Report 2012
31/10/12
MEMNuSep NOM 2012 AGM and EGM
30/10/12
MEMAppendix 3B
30/10/12
MEMNuSep Makes a 15% Placement
30/10/12PRICE SENSITIVE
MEMNuSep Updated Board Charters
30/10/12
MEMCorrection to Spin Out of PrIME Biologics And Update of Time
30/10/12
MEMNuSep clears shares held in suspense account
29/10/12
MEMNuSep 2012 AGM
15/10/12
MEMSpin Out of PrIME Biologics
15/10/12PRICE SENSITIVE
MEMCritical Milestone with Installation of PrIME unit in Singap
03/10/12PRICE SENSITIVE
MEMSubstantial Shareholder Notice
02/10/12
MEMAnnual Financial Report 30 June 2012
28/09/12
MEMNuSep Working Capital Advance and update on DCS Debt
27/09/12PRICE SENSITIVE
MEMResearch Report on NuSep
06/09/12
MEMNuSep announces 30 June 2012 Full Year Results
30/08/12PRICE SENSITIVE
MEMUpdate on PrIME Developments and impact on 30.06.12 results
28/08/12PRICE SENSITIVE
MEMNotice to holders of 35 cent options (NSPO)
21/08/12
(20min delay)
Last
0.5¢
Change
-0.001(16.7%)
Mkt cap ! $13.00M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $19.10K 3.821M

Buyers (Bids)

No. Vol. Price($)
11 4204169 0.5¢
 

Sellers (Offers)

Price($) Vol. No.
0.6¢ 5374720 3
View Market Depth
Last trade - 15.56pm 07/11/2024 (20 minute delay) ?
Last
0.6¢
  Change
-0.001 ( 10.0 %)
Open High Low Volume
0.5¢ 0.6¢ 0.5¢ 1763959
Last updated 15.05pm 07/11/2024 ?
MEM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.